Ngenbio Absorbs Subsidiary Jinmedica Through Merger
[Asia Economy Reporter Ji Yeon-jin] On the 12th, Enzen Bio announced that it will merge its subsidiary Jinmedica, which develops medical diagnostic kits.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Enzen Bio owns 100% of Jinmedica's issued shares, and this merger is a non-capital increase method in which Enzen Bio does not issue new shares for Jinmedica's stock.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
